CN Patent

CN109081828B — 聚(adp-核糖)聚合酶抑制剂、制备方法及用途

Assigned to Shanghai biling Biotechnology Co.,Ltd. · Expires 2021-03-26 · 5y expired

What this patent protects

本发明涉及一类如下通式I所示的化合物及其药学上可接受的盐、异构体、溶剂化物、多晶型物、稳定的同位素衍生物或前药、其制备方法及在药学上的应用，其中各基团的定义如说明书所述。本发明的化合物是聚(ADP‑核糖)聚合酶(poly(ADP‑ribose)polymerase，PARP)抑制剂，可用于治疗与PARP相关的疾病，如癌症、炎症疾病等。

USPTO Abstract

本发明涉及一类如下通式I所示的化合物及其药学上可接受的盐、异构体、溶剂化物、多晶型物、稳定的同位素衍生物或前药、其制备方法及在药学上的应用，其中各基团的定义如说明书所述。本发明的化合物是聚(ADP‑核糖)聚合酶(poly(ADP‑ribose)polymerase，PARP)抑制剂，可用于治疗与PARP相关的疾病，如癌症、炎症疾病等。

Drugs covered by this patent

Patent Metadata

Patent number: CN109081828B
Jurisdiction: CN
Classification: —
Expires: 2021-03-26
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai biling Biotechnology Co.,Ltd.
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.